January 4, 2016

, (GLOBE NEWSWIRE) -- (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that , President and Chief Executive Officer, is scheduled to present at the 34 Annual in , CA.

Event: 34th Annual
Date:
Time: / 11:00 a.m. ET

An audio webcast of the Company's presentation will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.

About

develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured is approximately 80%, making it a leading cause of death in the Additional information can be found on website at www.endologix.com. The Nellix System is an investigational device in . 


COMPANY CONTACT:

, CEO

, CFO

(949) 595-7200

www.endologix.com



INVESTOR CONTACTS:

 (646) 536-7030

 (646) 536-7020

Source:

News Provided by Acquire Media

Close window | Back to top

Endologix Inc. issued this content on 2016-01-04 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-11 22:09:23 UTC

Original Document: http://investor.endologix.com/releasedetail.cfm?ReleaseID=948639